Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $16.50.

A number of research firms recently commented on RNN. HC Wainwright reaffirmed a “buy” rating and issued a $19.50 target price on shares of Rexahn Pharmaceuticals in a research report on Monday. Ifs Securities reaffirmed an “outperform” rating on shares of Rexahn Pharmaceuticals in a research report on Monday, August 7th. Zacks Investment Research downgraded shares of Rexahn Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 13th. ValuEngine raised shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 2nd. Finally, Seaport Global Securities reaffirmed a “buy” rating and issued a $13.00 target price on shares of Rexahn Pharmaceuticals in a research report on Friday, October 6th.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sabby Management LLC purchased a new position in shares of Rexahn Pharmaceuticals in the 2nd quarter valued at about $706,000. Susquehanna International Group LLP purchased a new position in shares of Rexahn Pharmaceuticals in the 2nd quarter valued at about $2,905,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Rexahn Pharmaceuticals by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock valued at $2,937,000 after purchasing an additional 862,000 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/rexahn-pharmaceuticals-inc-rnn-given-consensus-recommendation-of-buy-by-analysts/1686460.html.

Rexahn Pharmaceuticals (RNN) traded down $0.09 during midday trading on Tuesday, hitting $1.85. 240,696 shares of the company were exchanged, compared to its average volume of 629,507. Rexahn Pharmaceuticals has a 1 year low of $0.38 and a 1 year high of $7.10.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Analyst Recommendations for Rexahn Pharmaceuticals (NYSEMKT:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.